GLP-1 Receptor Agonists: A Revolution in Obesity Treatment or a Passing Trend?
In recent times, there has been growing debate within the scientific community about the use of certain medications — so-called GLP-1 receptor agonists — as a strategy for weight loss. These include, for example, Ozempic, Wegovy, and Mounjaro. These medications are primarily used to treat type 2 diabetes and have proven effective not only in improving blood glucose control but also in promoting weight loss. However, this approach also has a downside that raises questions.
Why Have GLP-1 Medications Become So Popular?
“These medications — GLP-1 analogues such as semaglutide (Ozempic®), as well as newer dual-action medications such as tirzepatide (Mounjaro®) — are revolutionising the treatment of obesity, but it is important to separate the real potential of these medications from a passing ‘trend’,” warns doctor[Sergio Correa](https://www.instagram.com/sergcb93/).
How Do GLP-1 Receptor Agonists Work?
“To understand why medications such as semaglutide and tirzepatide have entered the healthcare field with such force, it is first essential to understand how they work. These medications are GLP-1 receptor agonists — a therapeutic class that mimics the action of a natural incretin hormone produced by our bodies after eating. As a result, they produce a strong feeling of satiety in the brain and slow gastric emptying, which naturally leads to a reduction in calorie intake,” the doctor adds.
Want to Learn More About These Medications?
If you want to learn more about GLP-1 receptor agonist treatments for weight loss or about the treatment of type 2 diabetes, explore these Oladoctor resources:
Comments
Be the first to comment on this article.
Sign in to leave a comment
Your comment will be visible to other readers after moderation.